The global HER2 Breast Cancer Test market size was estimated at USD 320.4 Million in 2021 and is expected to surpass around USD 628.1 Million by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.9% during the forecast period 2022 to 2030.
HER2 Breast Cancer Test Market: Overview
HER2 Breast Cancer Test Market: Key Drivers
Report Scope of the HER2 Breast Cancer Test Market
Report Coverage |
Details |
Market Size |
US$ 628.1 Million by 2030 |
Growth Rate |
CAGR of 6.9% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Test Type, End-user and Region, |
Companies Mentioned |
Abbott Molecular, Inc., Biogenex Laboratories, Inc., Leica Biosystems, Roche, Agilent Technologies, Mylab Discovery Solutions Pvt. Ltd. |
Telehealth Helps Avoid Delay in Breast Cancer Treatment amid Coronavirus Outbreak
The coronavirus outbreak has affected screening, diagnosis, treatment, and follow-up care for breast cancer. This is why the HER2 breast cancer test market is expanding in a staggered manner during the ongoing pandemic. Many individuals are fearing the contraction of the novel infection, leading to postponement and cancellation of treatments and screening. Nevertheless, telehealth services and mobile apps hold promising potentials to avoid delay in treatment of potential patients.
Since many countries have lifted their stay-at-home orders and allowed businesses to re-open, revenue flow is anticipated to grow in the HER2 breast cancer test market. Healthcare providers are extending their arms to provide essential and critical services to improve the patient quality of life during the ongoing pandemic.
Inaccurate HER2 Test Results with IHC Affect Market Growth
The HER2 breast cancer test market is expected to reach US$ 628.1 Mn by 2030. Immunohistochemistry (IHC) is being publicized as the gold standard for HER2 breast cancer testing. However, it has been found that some HER2 test results may be inaccurate, as different labs have different rules for classifying positive and negative HER2 status. Such findings are anticipated to affect market growth.
Inaccurate HER2 test results may deprive women diagnosed with breast cancer of proper care and treatment. Hence, healthcare providers in the HER2 breast cancer test market are increasing awareness about multiple reviewing of HER2 test results from more than one pathologist to attain certainty in outcomes.
FISH Test V/S IHC Test: Which is Better?
The FISH (Fluorescence In Situ Hybridization) test is not as widely available as compared to IHC. However, it has been found that FISH test in more accurate and reliable than IHC. In many cases, a lab will do the IHC test first and order FISH test only if the IHC results do not clearly show whether the cells are HER2-positive or negative.
The HER2 breast cancer test market is expected to register a CAGR of 6.9% during the forecast period. The growing popularity of FISH test helps to map the genetic material in a person’s cells. This test is used to visualize specific genes or portions of genes.
HER2 Testing Becoming Routine Practice for Newly Diagnosed Breast Cancer
IHC and FISH tests are gaining popularity for proper diagnosis, treatment, and follow-up care for HER2 breast cancer. HER2 testing is becoming a routine practice for newly diagnosed breast cancer in pathology. Bright-field in situ hybridization such as chromogenic in situ hybridization (CISH) has an advantage, since it allows histologic evaluation of tumors, utilizes ordinary microscope, can be fully automated, and leaves permanent signals for archival storage.
The CISH test is emerging as a suitable alternative to FISH test. Such trends are contributing to the growth of the HER2 breast cancer test market. For uniformity in accuracy and reproducibility of HER2 testing in breast cancer, the ASCO (American Society of Clinical Oncology) has released guidelines for the interpretation of HER2 status.
Market Segmentation: HER2 Breast Cancer Test Market
Regional Overview: HER2 Breast Cancer Test Market
Some of the prominent players in the HER2 Breast Cancer Test Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global HER2 Breast Cancer Test market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in HER2 Breast Cancer Test Market Study:
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Global HER2 Breast Cancer Test Market Forecast
4.3. Global HER2 Breast Cancer Test Market Outlook
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
5. Key Insights
5.1. Revenue Model
5.2. Pricing Analysis
5.3. COVID-19 Impact Analysis
6. Global HER2 Breast Cancer Test Market Analysis, by Test Type
6.1. Introduction
6.2. Global HER2 Breast Cancer Test Market Value Share Analysis, by Test Type
6.3. Global HER2 Breast Cancer Test Market Forecast, by Test Type
6.3.1. Immunohistochemistry (IHC)
6.3.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
6.4. Global HER2 Breast Cancer Test Market Analysis, by Test Type
6.5. Global HER2 Breast Cancer Test Market Attractiveness Analysis, by Test Type
7. Global HER2 Breast Cancer Test Market Analysis, by End-user
7.1. Introduction
7.2. Global HER2 Breast Cancer Test Market Value Share Analysis, by End-user
7.3. Global HER2 Breast Cancer Test Market Forecast, by End-user
7.3.1. Hospitals
7.3.2. Diagnostic Laboratories
7.4. Global HER2 Breast Cancer Test Market Analysis, by End-user
7.5. Global HER2 Breast Cancer Test Market Attractiveness Analysis, by End-user
8. Global HER2 Breast Cancer Test Market Analysis, by Region
8.1. Introduction
8.2. Global HER2 Breast Cancer Test Market Value Share Analysis, by Region
8.3. Global HER2 Breast Cancer Test Market Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
9. North America HER2 Breast Cancer Test Market Analysis
9.1. North America HER2 Breast Cancer Test Market Overview
9.2. North America HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Country
9.2.1. U.S.
9.2.2. Canada
9.3. North America HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Test Type
9.4. North America HER2 Breast Cancer Test Market Forecast, by Test Type
9.4.1. Immunohistochemistry (IHC)
9.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
9.5. North America HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by End-user
9.6. North America HER2 Breast Cancer Test Market Forecast, by End-user
9.6.1. Hospitals
9.6.2. Diagnostic Laboratories
10. Europe HER2 Breast Cancer Test Market Analysis
10.1. Europe HER2 Breast Cancer Test Market Overview
10.2. Europe HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Country/Sub-region
10.2.1. Germany
10.2.2. U.K.
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Europe HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Test Type
10.4. Europe HER2 Breast Cancer Test Market Forecast, by Test Type
10.4.1. Immunohistochemistry (IHC)
10.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
10.5. Europe HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by End-user
10.6. Europe HER2 Breast Cancer Test Market Forecast, by End-user
10.6.1. Hospitals
10.6.2. Diagnostic Laboratories
11. Asia Pacific HER2 Breast Cancer Test Market Analysis
11.1. Asia Pacific HER2 Breast Cancer Test Market Overview
11.2. Asia Pacific HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.2.1. China
11.2.2. Japan
11.2.3. India
11.2.4. Australia & New Zealand
11.2.5. Rest of Asia Pacific
11.3. Asia Pacific HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Test Type
11.4. Asia Pacific HER2 Breast Cancer Test Market Forecast, by Test Type
11.4.1. Immunohistochemistry (IHC)
11.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
11.5. Asia Pacific HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by End-user
11.6. Asia Pacific HER2 Breast Cancer Test Market Forecast, by End-user
11.6.1. Hospitals
11.6.2. Diagnostic Laboratories
12. Latin America HER2 Breast Cancer Test Market Analysis
12.1. Latin America HER2 Breast Cancer Test Market Overview
12.2. Latin America HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Country/Sub-region
12.2.1. Brazil
12.2.2. Mexico
12.2.3. Rest of Latin America
12.3. Latin America HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Test Type
12.4. Latin America HER2 Breast Cancer Test Market Forecast, by Test Type
12.4.1. Immunohistochemistry (IHC)
12.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
12.5. Latin America HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by End-user
12.6. Latin America HER2 Breast Cancer Test Market Forecast, by End-user
12.6.1. Hospitals
12.6.2. Diagnostic Laboratories
13. Middle East & Africa HER2 Breast Cancer Test Market Analysis
13.1. Middle East & Africa HER2 Breast Cancer Test Market Overview
13.2. Middle East & Africa HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.2.1. GCC Countries
13.2.2. South Africa
13.2.3. Rest of Middle East & Africa
13.3. Middle East & Africa HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Test Type
13.4. Middle East & Africa HER2 Breast Cancer Test Market Forecast, by Test Type
13.4.1. Immunohistochemistry (IHC)
13.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
13.5. Middle East & Africa HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by End-user
13.6. Middle East & Africa HER2 Breast Cancer Test Market Forecast, by End-user
13.6.1. Hospitals
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2019
14.3. Company Profiles
14.3.1. Abbott Laboratories
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. BioGenex
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. Agilent Technologies, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. Leica Biosystems
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. Roche
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. Mylab Discovery Solutions Pvt. Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview